These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10700875)

  • 1. [HIV: no virus eradication with HAART. Highly active antiretroviral therapy].
    Bubenzer RH
    Dtsch Med Wochenschr; 2000 Feb; 125(6):A11. PubMed ID: 10700875
    [No Abstract]   [Full Text] [Related]  

  • 2. HAART reduces virus in women's genital tracts.
    AIDS Alert; 1999 Mar; 14(3):30-1. PubMed ID: 11366213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HIV eradication--facts and fiction].
    Jaeger H; Wolf E
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():72-3. PubMed ID: 19024923
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E; Galli L; Zazzi M; de Martino M
    J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction procedures.
    La Sala GB; Pilotti E; Nicoli A; Pinelli S; Villani MT; Ronzi P; Zendri E; Re MC; Magnani G; Casoli C
    AIDS; 2007 Jan; 21(3):377-9. PubMed ID: 17255749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
    Kulkosky J; Pomerantz RJ
    Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.
    Kulkosky J; Nunnari G; Otero M; Calarota S; Dornadula G; Zhang H; Malin A; Sullivan J; Xu Y; DeSimone J; Babinchak T; Stern J; Cavert W; Haase A; Pomerantz RJ
    J Infect Dis; 2002 Nov; 186(10):1403-11. PubMed ID: 12404155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiretroviral therapy in 2004].
    Jablonowski H
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
    Mwamburi DM; Wilson IB; Jacobson DL; Spiegelman D; Gorbach SL; Knox TA; Wanke CA
    Clin Infect Dis; 2005 Jan; 40(1):167-73. PubMed ID: 15614708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV therapeutics: points from the recent literature.
    Laurence J
    AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HIV infection].
    Tachikawa N
    Nihon Rinsho; 2006 Jul; 64(7):1333-7. PubMed ID: 16838653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
    Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.